Spero Therapeutics, Inc.
Spero Therapeutics Announces Third Quarter 2026 Operating Results and Provides Business Update
SP001, an anti-CD40L antibody with potential across multiple immune-mediated diseases, advancing toward Phase 2 initiation in Immunoglobulin…